Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
An Integrated Bioinformatics Analysis of the Potential Regulatory Effects of Mir-21 on T-Cell Related Target Genes in Multiple Sclerosis Publisher



Manian M1 ; Sohrabi E2 ; Eskandari N3 ; Assarehzadegan MA1, 4 ; Ferns GA5 ; Nourbakhsh M6 ; Jazayeri MH1, 4 ; Nedaeinia R7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Medical Genetics and Molecular Biology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Immunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran
  5. 5. Brighton and Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex, BN1 9PH, United Kingdom
  6. 6. Department of Biochemistry and Nutrition, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
  7. 7. Pediatric Inherited Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Avicenna Journal of Medical Biotechnology Published:2021


Abstract

Background: Overexpression of miR-21 is a characteristic feature of patients with Multiple Sclerosis (MS) and is involved in gene regulation and the expression enhance-ment of pro-inflammatory factors including IFNγ and TNF-α following stimulation of T-cells via the T Cell Receptor (TCR). In this study, a novel integrated bioinformatics analysis was used to obtain a better understanding of the involvement of miR-21 in the development of MS, its protein biomarker signatures, RNA levels, and drug interactions through existing microarray and RNA-seq datasets of MS. Methods: In order to obtain data on the Differentially Expressed Genes (DEGs) in patients with MS and normal controls, the GEO2R web tool was used to analyze the Gene Expression Omnibus (GEO) datasets, and then Protein-Protein Interaction (PPI) networks of co-expressed DEGs were designed using STRING. A molecular network of miRNA-genes and drugs based on differentially expressed genes was created for T-cells of MS patients to identify the targets of miR-21, that may act as important regu-lators and potential biomarkers for early diagnosis, prognosis and, potential therapeutic targets for MS. Results: It found that seven genes (NRIP1, ARNT, KDM7A, S100A10, AK2, TGFβR2, and IL-6R) are regulated by drugs used in MS and miR-21. Finally, three overlapping genes (S100A10, NRIP1, KDM7A) were identified between miRNA-gene-drug network and nineteen genes as hub genes which can reflect the pathophysiology of MS. Conclusion: Our findings suggest that miR-21 and MS-related drugs can act synergisti-cally to regulate several genes in the existing datasets, and miR-21 inhibitors have the potential to be used in MS treatment. © 2021, Avicenna Journal of Medical Biotechnology. All rights reserved.
Related Docs
View other Related Docs
1. The Role of Micrornas Involved in the Disorder of Blood–Brain Barrier in the Pathogenesis of Multiple Sclerosis, Frontiers in Immunology (2023)
2. Mir-145 and Mir20a-5P Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients, Journal of Molecular Neuroscience (2017)
3. Analysis of the Expression of Mir-34A, Mir-199A, Mir-30C and Mir-19A in Peripheral Blood Cd4+T Lymphocytes of Relapsing-Remitting Multiple Sclerosis Patients, Gene (2018)
4. Micrornas: Key Modulators of Disease-Modifying Therapies in Multiple Sclerosis : Pancreatic Cancer Is One of the Lethal Malignant Tumours in the World.In This Study, We Investigated the Car T-Cell Therapy of Pancreatic Cancer, International Reviews of Immunology (2020)
5. Comparison of the Expression of Mir-326 Between Interferon Beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis, Cell Journal (2020)
6. Microrna-29B Variants and Mxa Expression Change During Interferon Beta Therapy in Patients With Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2019)
7. Mir-326 and Mir-26A, Two Potential Markers for Diagnosis of Relapse and Remission Phases in Patient With Relapsing-Remitting Multiple Sclerosis, Gene (2014)
8. Upregulation of Cd4+ T-Cell Derived Mir-223 in the Relapsing Phase of Multiple Sclerosis Patients, Cell Journal (2016)
Experts (# of related papers)
View all Related Experts
Masoud Etemadifar (32)
Vahid Shaygannejad (21)
Other Related Docs
9. Mir-504 Expression Level Is Increased in Multiple Sclerosis Patients Responder to Interferon-Beta, Journal of Neuroimmunology (2020)
10. Comparison of Expression Levels of Mir-29B-3P and Mir-326 in T Helper-1 and T Helper-17 Cells Isolated From Responsive and Non-Responsive Relapsing-Remitting Multiple Sclerosis Patients Treated With Interferon-Beta, Iranian Journal of Allergy, Asthma and Immunology (2020)
11. Genetic Variation in Intergenic and Exonic Mirna Sequence and Risk of Multiple Sclerosis in the Isfahan Patients, Iranian Journal of Allergy, Asthma and Immunology (2018)
12. Study of the Correlation Between Mir-106A, Mir-125B, and Mir-330 on Multiple Sclerosis Patients by Targeting Tnfsf4 and Sp1 in Nf-Κb/Tnf-Α Pathway: A Case-Control Study, Cell Journal (2022)
13. Identification of Potential Biomarkers in the Peripheral Blood Mononuclear Cells of Relapsing–Remitting Multiple Sclerosis Patients, Inflammation (2022)
14. Evaluation of the Expressed Mir‑129 and Mir‑549A in Patients With Multiple Sclerosis, Advanced Biomedical Research (2021)
15. Connection of Mir-185 and Mir-320A Expression Levels With Response to Interferon-Beta in Multiple Sclerosis Patients, Multiple Sclerosis and Related Disorders (2020)
16. Lncrnas Associated With Multiple Sclerosis Expressed in the Th1 Cell Lineage, Journal of Cellular Physiology (2019)
17. Semaphorin-3A As an Immune Modulator Is Suppressed by Microrna-145-5P, Cell Journal (2018)
18. Therapeutic Inhibition of Microrna-21 (Mir-21) Using Locked-Nucleic Acid (Lna)-Anti-Mir and Its Effects on the Biological Behaviors of Melanoma Cancer Cells in Preclinical Studies, Cancer Cell International (2020)
19. Investigation of Erg Gene Expression in Iranian Patients With Multiple Sclerosis, Immunological Investigations (2018)
20. The Effect of Beta Interferon on the Expression of Mir-145 in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2016)
21. Il-23 Plasma Level Measurement in Relapsing Remitting Multiple Sclerosis (Rrms) Patients Compared to Healthy Subjects, Immunological Investigations (2015)
22. Microrna-92A Drives Th1 Responses in the Experimental Autoimmune Encephalomyelitis, Inflammation (2019)
23. Mir-141 and Mir-200A, Revelation of New Possible Players in Modulation of Th17/Treg Differentiation and Pathogenesis of Multiple Sclerosis, PLoS ONE (2015)
24. Potential Biomarker and Therapeutic Lncrnas in Multiple Sclerosis Through Targeting Memory B Cells, NeuroMolecular Medicine (2020)
25. A Functional Microrna Binding Site Variant in Il-23R Gene in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Is There Any Correlation?, Molecular Biology Reports (2022)
26. Cytokine Gene Expression in Newly Diagnosed Multiple Sclerosis Patients, Iranian Journal of Allergy, Asthma and Immunology (2015)
27. The Effect of Interferon-Beta Therapy on T-Helper 17/Mir-326 and T-Helper 1/Mir-29B-3P Axis in Relapsing-Remitting Multiple Sclerosis Patients, NeuroImmunoModulation (2022)
28. Decreased Expression of Hsa-Mir-142-3P and Hsa-Mir-155-5P in Common Variable Immunodeficiency and Involvement of Their Target Genes and Biological Pathways, Allergologia et Immunopathologia (2025)
29. Multiple Sclerosis: Pathophysiology, Clinical Features, Diagnosis, and Management, Neuroinflammation (2011)
30. Impact of Mirna-Binding Site Polymorphisms in Stat3 Gene on Occurrence and Clinical Characteristics of Systemic Lupus Erythematosus, Lupus (2022)
31. Evaluation of Microrna Expression Pattern (Mir-28, Mir-181A, Mir-34A, and Mir-31) in Patients With Covid-19 Admitted to Icu and Diabetic Covid-19 Patients, Intervirology (2023)
32. Apamin Administration Impact on Mir-219 and Mir-155-3P Expression in Cuprizone Induced Multiple Sclerosis Model, Molecular Biology Reports (2020)
33. Locked Nucleic Acid Anti-Mir-21 Inhibits Cell Growth and Invasive Behaviors of a Colorectal Adenocarcinoma Cell Line: Lna-Anti-Mir As a Novel Approach, Cancer Gene Therapy (2016)
34. Exploring Conserved Mrna-Mirna Interactions in Colon and Lung Cancers, Gastroenterology and Hepatology from Bed to Bench (2017)
35. Biclustering of Coherent Time Series in Microarray Data, Journal of Isfahan Medical School (2012)
36. Evaluation of Silencing Effect of Mir-133A-5P Mimic on Tim-3 Expression in Aml (Hl-60) Cell Line, Indian Journal of Clinical Biochemistry (2020)
37. Expression of Hsa-Mir-204, Runx2, Pparγ, and Bcl2 in Bone Marrow Derived Mesenchymal Stem Cells From, Cell Journal (2017)
38. Identification of Key Genes and Biological Regulatory Mechanisms in Diabetic Nephropathy: Meta-Analysis of Gene Expression Datasets; [Identificacion De Genes Clave Y Mecanismos Reguladores Biologicos En La Nefropatia Diabetica: Metaanalisis De Conjuntos De Datos De Expresion Genica], Nefrologia (2023)
39. Neutralizing Antibodies in Multiple Sclerosis Patients on Weekly Intramuscular Avonex and Biosimilar Interferon Beta-1A (Cinnovex): Comparing Results of Measurements in Two Different Laboratories, Journal of Immunological Methods (2013)
40. Biased Treg/Th17 Balance Away From Regulatory Toward Inflammatory Phenotype in Relapsed Multiple Sclerosis and Its Correlation With Severity of Symptoms, Journal of Neuroimmunology (2013)
41. Mir-196: Emerging of a New Potential Therapeutic Target and Biomarker in Colorectal Cancer, Molecular Biology Reports (2020)
42. Increased Serum Level of Il-37 in Patients With Multiple Sclerosis and Neuromyelitis Optica, Acta Neurologica Belgica (2015)
43. The Effect of Plasma Exchange on the Expression of Foxp3 and Rorc2 in Relapsed Multiple Sclerosis Patients, Iranian Journal of Immunology (2015)
44. Current Status and Perspectives Regarding Lna-Anti-Mir Oligonucleotides and Microrna Mir-21 Inhibitors As a Potential Therapeutic Option in Treatment of Colorectal Cancer, Journal of Cellular Biochemistry (2017)
45. Upregulation of Mtor, Rps6kb1, and Eif4ebp1 in the Whole Blood Samples of Iranian Patients With Multiple Sclerosis Compared to Healthy Controls, Metabolic Brain Disease (2020)
46. Association of Aire Polymorphism and the Susceptibility to Multiple Sclerosis in Iranian Population, Avicenna Journal of Medical Biotechnology (2018)
47. The Importance of Snps at Mirna Binding Sites As Biomarkers of Gastric and Colorectal Cancers: A Systematic Review, Journal of Personalized Medicine (2022)
48. Multiple Sclerosis: Clinical Features, Pathophysiology, Neuroimaging and Future Therapies, Future Neurology (2009)
49. Cerebrospinal Fluid and Serum Markers of Inflammation in Patients With Multiple Sclerosis, Advances in Neuroimmune Biology (2017)
50. Interleukin-33 Plasma Levels in Patients With Relapsing-Remitting Multiple Sclerosis, Biomolecular Concepts (2017)